Results 101 to 110 of about 72,198 (215)

Myelofibrosis predicts deep molecular response 4.5 in chronic myeloid leukaemia patients initially treated with imatinib: An extensive, multicenter and retrospective study to develop a prognostic model

Clinical and Translational Medicine
Tian Zeng, Xiudi Yang, Yi Wang, Dijiong Wu, Weiying Feng, Ying Lu, Xiaoqiong Zhu, Lirong Liu, Mei Zhou, Li Zhang, Yanping Shao, Honglan Qian, Feng Zhu, Yu Chen, Dan Cao, Li Huang, Xiaoning Feng, Lili Chen, Gang Zhang, Jing Le, Weiguo Zhu, Yongming Xia, Yanxia Han, Yongqing Jia, Guoyan Tian, Hui Zhou, Linjuan Xu, Xiufeng Yin, Qinli Tang, Yuefeng Zhang, Guoli Yao, Xianghua Lang, Kaifeng Zhang, Xiujie Zhou, Junbin Guo, Jinming Tu, Jianzhi Zhao, Gongqiang Wu, Huiqi Zhang, Xiao Wu, Qiulian Luo, Lihong Cao, Binbin Chu, Wei Jiang, Haiying Wu, Liansheng Huang, Meiwei Hu, Muqing He, Jingjing Zhu, Hongyan Tong, Jie Jin, Jian Huang   +51 more
doaj   +1 more source

Candidate Regulatory Relationship and Expression Correlation Between miR-33a-5p and ANK3 in Chronic Myeloid Leukemia. [PDF]

Curr Issues Mol Biol
Kar N, Misir S, Ozer Yaman S, Akidan O, Hepokur C, Aliyazicioglu Y.   +5 more
europepmc   +1 more source

Integrating Asciminib into the Evolving Treatment Landscape of Chronic Myeloid Leukemia: A Canadian Perspective. [PDF]

J Blood Med
Kim DDH, Busque L, Hillis C, Laneuville P, Savoie ML.   +4 more
europepmc   +1 more source

Composite marginal likelihood estimation of higher‐order diagnostic classification models under high dimensionality

British Journal of Mathematical and Statistical Psychology, EarlyView.
Abstract Although full‐information maximum likelihood (FIML) estimation is widely used for diagnostic classification models (DCMs), its computational efficiency deteriorates sharply in high‐dimensional settings. This scalability challenge is increasingly critical as DCMs are applied to large‐scale assessments, psychological testing and longitudinal ...
Minho Lee, Yon Soo Suh
wiley   +1 more source

Dual-Driver Myeloproliferative Neoplasm: Concurrent p190 <i>BCR::ABL1</i> CML and <i>JAK2</i> V617F Mutation: A Case Report and Literature Review. [PDF]

Case Rep Hematol
Elkady M, Jin Y, Zhao W.
europepmc   +1 more source

Targeting KRAS for cancer therapy

British Journal of Pharmacology, EarlyView.
In recent years, therapeutics targeted against KRAS proto‐oncogene GTPase (KRAS)‐mutant cancers have seen significant progress. Herein we outline the biology and epidemiology of KRAS alterations at the lineage and allele levels, reviewing the clinical evidence for KRASG12C inhibition from the discovery of the recessive switch pocket to sotorasib ...
Jianlong Jia, Ruonan Liu, Tonia A. Adamide, Isis E. Fernandez, Georgios T. Stathopoulos   +4 more
wiley   +1 more source

Symptom burden in myeloproliferative neoplasms: clinical correlates, dynamics, and survival impact—a study of 784 patients from the Quebec MPN research group

Blood Cancer Journal
Alisa Poullet, Lambert Busque, Shireen Sirhan, Robert Delage, Ghislain Cournoyer, Ines Chamakhi, Danielle Talbot, Luigina Mollica, Daniele Marceau, Vincent Ethier, Pierre Desjardins, Harold J. Olney, Michaël Harnois, Natasha Szuber   +13 more
doaj   +1 more source

A fatal posterior-fossa chloroma masquerading as tuberculous meningitis after peripartum BCR-ABL1 inhibitor cessation - a case report. [PDF]

Leuk Res Rep
Zutshi B, Garg S, Bharti P, Kumar A, Chakraborty A, Miglani S, Meena AK, Chahal AS, Ghosh SS.   +8 more
europepmc   +1 more source

CD93—An emerging vascular target in cancer therapy

British Journal of Pharmacology, EarlyView.
Abstract CD93 is a single‐pass transmembrane glycoprotein that belongs to the C‐type lectin domain group XIV family of proteins. Although it is known to be expressed in other cell types, namely, in some subsets of immune cells, CD93 is primarily expressed on endothelial cells, where it acts as a crucial regulator of angiogenesis.
Beatriz de Alves Pereira, Stefano Barbera, Roberta Lugano, Anna Dimberg   +3 more
wiley   +1 more source

New insights into beech wood structure through photothermal AFM-IR. [PDF]

RSC Adv
E I A, C P, B W.
europepmc   +1 more source